A Phase 1 Open Label, Multi-Arm, Multicenter Study of MK-1308 in Combination With Pembrolizumab for Subjects With Advanced Solid Tumors
Phase of Trial: Phase I
Latest Information Update: 15 Feb 2019
At a glance
- Drugs MK 1308 (Primary) ; Pembrolizumab
- Indications Non-small cell lung cancer; Small cell lung cancer; Solid tumours
- Focus Adverse reactions; Therapeutic Use
- Sponsors Merck Sharp & Dohme
- 07 Feb 2019 Planned End Date changed from 7 Oct 2022 to 8 Mar 2023.
- 07 Feb 2019 Planned primary completion date changed from 7 Oct 2022 to 8 Mar 2023.
- 14 Dec 2018 Planned number of patients changed from 168 to 308.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History